AI assistant
Integrated Proteins Ltd. Interim / Quarterly Report 2026
63180_rns_2026-05-28_194971ae-90a4-48f1-804e-9a300bf519ac.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
INTEGRATED PROTEINS LIMITED
Manek Centre, Office No 218, P N Marg, Jamnagar - 361008, Gujarat, India
Phone: 9428817400
Email ID: [email protected]
Website: www.integratedproteins.com
CIN: L62013GJ1992PLC018426
Date: 28th May, 2026
To,
BSE Limited
Phiroz Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
Scrip Code: 519606
Subject: Publication of Standalone Audited Financial Results for Quarter and Financial Year Ended on 31st March, 2026 in Newspaper.
Pursuant to Regulation 47 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015, the Audited Financial Results (Standalone) for the Fourth Quarter and Financial Year Ended 31st March, 2026 were duly published in following newspaper:
- Economics Times (English)
- Navgujarat Samay (Gujarati)
The copy of published Results is enclosed for your reference.
Please take the same on your record and oblige.
For, Integrated Proteins Limited
Karanj Dharmeshbhai Joshi
Managing Director
Din: 10848249
(Encl. as above)
कायमालिसवत खेकसप्रेस
कम्बरवार, मुरूवात, ता. 87, 8995
93
K.C.P.SUGAR AND INDUSTRIES CORPORATION LIMITED
Registered Office: Transaktielive Building / No.239, Kone Saha, Chennai - 698 000
CIN: L54327N1995PL00333M
Tel: 044 - 28504827 / e-mail: [email protected] / www.kcsugaran.com
| PARTICULARS | Quarter Ended | Year Ended | Quarter Ended | Year Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31-03-2026 | 31-12-2025 | 31-03-2025 | 31-03-2026 | 31-03-2026 | 31-03-2025 | 31-03-2026 | 31-03-2026 | 31-03-2025 | 31-03-2026 | 31-03-2025 | 31-03-2026 | |
| 41-01-2026 | 41-10-2025 | 41-01-2025 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2026 | 41-01-2026 | 41 | |
| 1 | 1st Half day to the period before tax | 41-01-2026 | 41-01-2026 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2025 | 41-01-2025 | 41-01-2025 |
| 2 | Occupation and Extraordinary Items | 41-01-2026 | 41-01-2026 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2025 | 41-01-2025 | 41-01-2025 |
| 3 | 1st Half day to the period before tax | 41-01-2026 | 41-01-2026 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2025 | 41-01-2025 | 41-01-2025 |
| 4 | Occupation and Extraordinary Items | 41-01-2026 | 41-01-2026 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2025 | 41-01-2025 | 41-01-2025 |
| 5 | 2nd Half day to the period before tax | 41-01-2026 | 41-01-2026 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2025 | 41-01-2025 | 41-01-2025 |
| 6 | Occupation and Extraordinary Items | 41-01-2026 | 41-01-2026 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2026 | 41-01-2026 | 41-01-2025 | 41-01-2025 | 41-01-2025 | 41-01-2025 |
| INTEGRATED PROTEINS LIMITED Office No. 218, Manek Centre, Pandit Nehru Marg, Patel Colony, Jannagar, Gujarat, India, 361606. Phone: (0289) 2551901 Fax: (0289) 2552566 Email ID: [email protected] / Website: www.integratedproteins.com CIN: L62013GJ1992PLC018426 | |
|---|---|
| Standalone Statement of Audited Financial Results for the Quarter/ Year Ended 31-03-2026 | |
| Particulars | (No. In Lakh except per share data) |
| --- | --- |
| 21-01-2026 | |
| 1 | |
| 1 | Total Income from operations |
| 2 | Net Profit (loss) for the period (before tax, Exceptional and Extraordinary Items) |
| 3 | Net Profit (loss) for the period before tax (after Exceptional and/or Extraordinary Items) |
| 4 | Net Profit (loss) for the period after tax (after Exceptional and/or Extraordinary Items) |
| 5 | Total Comprehensive Income for the period Compulsory Profit (loss) for the period (after Accredited Other Comprehensive Income) |
| 6 | Paid-up equity share capital (Face Value of Rs. 15/- per equity share) |
| 7 | Reserves (Excluding Revaluation Reserves) as shown in Audited Balance sheet |
| 8 | Earnings per share |
| 1 | 1. Basis for continuing operations (Non Annualised) |
| 2 | 2. Diluted for continuing operations (Non Annualised) |
| 3 | 3.Basic and Diluted from Discontinued operations (Non - Annualised) |
Basic and Diluted Earnings per share are not annualised except for the year ended 31, March 2026.
Notes:
Notes to Standalone Audited Financials results for the year ended 31st March 2026:
1. The above audited standalone financial results for the quarter and year ended March 31, 2026 have been reviewed by the Audit Bureau of India. The report is submitted to the Audit Bureau of India on 31 March 2026. Appointed by the Budget Office (No. 018426) in their respective meetings held on May 29, 2026. The statutory auditors have expressed an unmodified opinion.
2. The above Audited financial results have been prepared by the Finance and Commerce Office of the Government of India (FMC) and the Department of Commerce of India (DMC) to support the analysis of the financial statements presented in the above report. The report is submitted to the Audit Bureau of India on 31 March 2026. Appointed by the Budget Office (No. 018426) in their respective meetings held on May 29, 2026.
PHARMACIA 2017-08-25
PHARMACIA EXPRESS
| Name of Patient | Nagoya Office - Honshu Hospital, Tokyo 101-4-202-101, Honshu Hospital, Tokyo, Japan 100-021 |
|---|---|
| RESEARCH INSTITUTE | |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | |
| Body Mass: 1.1 lbs for 24 h, 24 hours, 8 days (day from 12 months), 12 hours (day from 12 months), 12 hours (day from 12 months) | |
| Body Mass: 1.1 lbs | |
| Body Mass: 1.1 lbs | |
| Body Mass: 1.1 lbs | |
| Body Mass: 1.1 lbs | |
| Body Mass: 1.1 lbs | |
| Body Mass: 1.1 lbs | |
| Body Mass: 1.1 lbs | |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | |
| Body Mass: 1.1 lbs | |
| Body Mass: 1.1 lbs | |
| Body Mass: 1.1 lbs | |
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
| --- | --- |
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
| 3. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
| Date of Case | Date & Classified |
| --- | --- |
| 06/25/2016 | 10:45:2016 |
| 06/25/2016 | 10:45:2016 |
| 06/25/2016 | 10:45:2016 |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |
ADVERTISING
| Name of Patient | Nagoya Hospital, Tokyo 101-4-202-101, Tokyo 101-4-202-101 |
|---|---|
| RESEARCH INSTITUTE | Hospital |
| 1. The Location Determined (Nonsteroidal, Electrolyte, and Other Antihistamines) | Hospital |
| 2. The Use of Anticholinergics (Lethal, Thylakoid, and Other Anticholinergics) | Hospital |